Advaxis, Inc. Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--The US Patent and Trademark office approved Advaxis Incorporated (OTCBB: ADXS) patent-application Compositions and Methods for Enhancing the Immunogenicity of Antigens (Application # US2005/0118184 A1). This patent application covers the use of Listeria monocytogenes (Lm) protein ActA and fragments of this protein for use in the creation of antigen fusion proteins.